Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Heliyon ; 8(4): e09317, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-35520616

RESUMEN

The next generation of wireless communication networks will rely heavily on machine learning and deep learning. In comparison to traditional ground-based systems, the development of various communication-based applications is projected to increase coverage and spectrum efficiency. Machine learning and deep learning can be used to optimize solutions in a variety of applications, including antennas. The latter have grown popular for obtaining effective solutions due to high computational processing, clean data, and large data storage capability. In this research, machine learning and deep learning for various antenna design applications have been discussed in detail. The general concept of machine learning and deep learning is introduced. However, the main focus is on various antenna applications, such as millimeter wave, body-centric, terahertz, satellite, unmanned aerial vehicle, global positioning system, and textiles. The feasibility of antenna applications with respect to conventional methods, acceleration of the antenna design process, reduced number of simulations, and better computational feasibility features are highlighted. Overall, machine learning and deep learning provide satisfactory results for antenna design.

3.
Indian J Crit Care Med ; 25(4): 416-420, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-34045809

RESUMEN

INTRODUCTION: The main purpose of this study was to evaluate the effectiveness of graded early mobilization on psychomotor status and duration of ICU stay of patients with mechanical ventilation. MATERIALS AND METHODS: Design: Quasi-experimental study.Setting: BRB Hospitals Limited, Dhaka, Bangladesh. A reputed 500-beddedgeneral hospital with 30 ICU beds.Participants: A total of 30 patients were selected as participants in the study from the hospital. 15 patients were included in the ICU treatment group and the remaining 15 were in the intervention group using the purposive sampling method.Scales used: Functional independence measure (FIM) scale and 7 point generalized anxiety depression (GAD-7) scale.Intervention: Graded early mobilization was provided as an intervention to all participants of the intervention group by a professionally qualified ICU physiotherapist for 10 sessions. Most of the patients received multiple sessions of intervention within a day. RESULTS: In the control group mean FIM score was 17.40 (SD±4.88), and in the intervention group mean score was 65.70 (SD±12.18). The mean difference was statistically significant in the 't' test (p-value > 0.001). In the control group, the mean GAD-7 score was 19.50 (SD±2.71), and in the intervention group the mean GAD-7 score was 7.5 (SD±2.59). The mean difference was statistically significant in the 't' test. (p-value > 0.001). The mean length of ICU stay in the control group was 5.60 (SD±1.07) and in the intervention group it was 3.10 (SD±0.56). The mean difference was statistically significant in the 't' test (p-value > 0.001). CONCLUSION: This research showed that graded early mobilization was highly effective to improve the motor and psychological status of mechanically ventilated patients and reduce their length of ICU stay. HOW TO CITE THIS ARTICLE: Das B, Saha S, Kabir F, Hossain S. Effect of Graded Early Mobilization on Psychomotor Status and Length of Intensive Care Unit Stay in Mechanically Ventilated Patients. Indian J Crit Care Med 2021;25(4):416-420.

4.
Drug Deliv Transl Res ; 8(3): 484-495, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29508159

RESUMEN

Most medications targeting optic neuropathies are administered as eye drops. However, their corneal penetration efficiencies are typically < 5%. There is a clear, unmet need for novel transcorneal drug delivery vehicles. To this end, we have developed a stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for controlled release of poorly bioavailable drugs into the aqueous humor of the eye. The hydrogel is formulated as a composite of hyaluronic acid (HA) and methylcellulose (MC). The amphiphilic nanoparticles are composed of poly(ethylene oxide) (PEO) and poly(lactic acid) (PLA). Experimental design aided the identification of hydrogel composition and nanoparticle content in the formulation, and the formulation reliably switched between thixotropy and temperature-dependent rheopexy when it was tested in a rheometer under conditions that simulate the ocular surface, including blinking. These properties should ensure that the formulation coats the cornea through blinking of the eyelid and facilitate application of the medication as an eye drop immediately prior to the patient's bedtime. We subsequently tested the efficacy of our formulation in whole-eye experiments by loading the nanoparticles with cannabigerolic acid (CBGA). Our formulation exhibits over a 300% increase in transcorneal penetration over control formulations. This work paves the way for the introduction of novel products targeting ocular diseases to the market.


Asunto(s)
Benzoatos/administración & dosificación , Córnea/metabolismo , Hidrogeles/administración & dosificación , Nanopartículas/administración & dosificación , Administración Oftálmica , Animales , Benzoatos/metabolismo , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/química , Composición de Medicamentos , Escherichia coli/genética , Escherichia coli/metabolismo , Ácido Hialurónico/administración & dosificación , Ácido Hialurónico/química , Hidrogeles/química , Metilcelulosa/administración & dosificación , Metilcelulosa/química , Nanopartículas/química , Poliésteres/administración & dosificación , Poliésteres/química , Polietilenglicoles/administración & dosificación , Polietilenglicoles/química , Reología , Porcinos
5.
Curr Cancer Drug Targets ; 17(8): 707-721, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28359244

RESUMEN

BACKGROUND: Mutations in proto-oncogenes and tumor suppressor genes make cancer cells proliferate indefinitely. As they possess almost all mechanisms for cell proliferation and survival like healthy cells, it is difficult to specifically target cancer cells in the body. Current treatments in most of the cases are harmful to healthy cells as well. Thus, it would be of great prudence to target specific characters of cancer cells. Since cancer cells avidly use glucose and glutamine to survive and proliferate by upregulating the relevant enzymes and their specific isoforms having important regulatory roles, it has been of great interest recently to target the energy-related metabolic pathways as part of the therapeutic interventions. OBJECTIVE: This paper summarizes the isozymes overexpressed in breast cancer, their roles of energy metabolism and cross-talks with other important signaling pathways in regulating proliferation, invasion and metastasis in breast cancer. METHOD: Information has been collected from recently published literature available on Google Scholar and PubMed. Where available, in vivo results were given more importance over in vitro works. RESULT: Like many other cancers, breast cancer shows increased dependence on glycolysis rather than mitochondrial respiration, the main energy source in healthy cells. Cancer cells alter the cellular energy system in a way that helps minimize level of reactive oxygen species and simultaneously produce enough macromolecules- proteins, lipids and nucleotides for cellular proliferation. The altered system enables the cells to grow, proliferate, metastasize and to develop drug resistance. Certain isozymes of metabolic enzymes are overexpressed in breast cancer and the degree of expression of these enzymes vary among subtypes. CONCLUSION: A clear understanding of the variations of energy metabolism in different molecular subtypes of breast cancer would help in treating each type with a very customized, safer and efficient treatment regimen. Anti-cancer drugs or RNAi or combination of both targeting cancer cell specific isozymes of metabolic enzymes mentioned in this article could offer a great treatment modality for breast cancer.


Asunto(s)
Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Metabolismo Energético/efectos de los fármacos , Animales , Proliferación Celular/efectos de los fármacos , Femenino , Humanos , Mitocondrias/efectos de los fármacos , Transducción de Señal/efectos de los fármacos
6.
Mol Cancer Ther ; 14(4): 982-93, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25673819

RESUMEN

The IGFI receptor promotes malignant progression and has been recognized as a target for cancer therapy. Clinical trials with anti-IGFIR antibodies provided evidence of therapeutic efficacy but exposed limitations due in part to effects on, and the compensatory function of, the insulin receptor system. Here, we report on the production, characterization, and biologic activity of a novel, IGF-targeting protein (the IGF-Trap) comprising a soluble form of hIGFIR and the Fc portion of hIgG1. The IGF-Trap has a high affinity for hIGFI and hIGFII but low affinity for insulin, as revealed by surface plasmon resonance. It efficiently blocked IGFIR signaling in several carcinoma cell types and inhibited tumor cell proliferation, migration, and invasion in vitro. In vivo, the IGF-Trap showed favorable pharmacokinetic properties and could suppress the growth of established breast carcinoma tumors when administered therapeutically into tumor-bearing mice, improving disease-free survival. Moreover, IGF-Trap treatment markedly reduced experimental liver metastasis of colon and lung carcinoma cells, increasing tumor cell apoptosis and reducing angiogenesis. Finally, when compared with an anti-IGFIR antibody or IGF-binding protein-1 that were used at similar or higher concentrations, the IGF-Trap showed superior therapeutic efficacy to both inhibitors. Taken together, we have developed a targeted therapeutic molecule with highly potent anticancer effects that could address limitations of current IGFIR-targeting agents.


Asunto(s)
Antineoplásicos/farmacología , Carcinoma/metabolismo , Carcinoma/patología , Receptor IGF Tipo 1/antagonistas & inhibidores , Proteínas Recombinantes de Fusión/farmacología , Animales , Especificidad de Anticuerpos , Antineoplásicos/química , Antineoplásicos/aislamiento & purificación , Células CHO , Carcinoma/tratamiento farmacológico , Carcinoma/mortalidad , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Cricetulus , Modelos Animales de Enfermedad , Humanos , Factor I del Crecimiento Similar a la Insulina/metabolismo , Factor II del Crecimiento Similar a la Insulina/metabolismo , Cinética , Ratones , Metástasis de la Neoplasia , Unión Proteica , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/aislamiento & purificación , Transducción de Señal/efectos de los fármacos , Carga Tumoral/efectos de los fármacos , Ensayos Antitumor por Modelo de Xenoinjerto
8.
Mol Cancer Ther ; 11(7): 1477-87, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22562986

RESUMEN

Deregulation of TGF-ß superfamily signaling is a causative factor in many diseases. Here we describe a protein engineering strategy for the generation of single-chain bivalent receptor traps for TGF-ß superfamily ligands. Traps were assembled using the intrinsically disordered regions flanking the structured binding domain of each receptor as "native linkers" between two binding domains. This yields traps that are approximately threefold smaller than antibodies and consists entirely of native receptor sequences. Two TGF-ß type II receptor-based, single-chain traps were designed, termed (TßRII)2 and (TßRIIb)2, that have native linker lengths of 35 and 60 amino acids, respectively. Both single-chain traps exhibit a 100 to 1,000 fold higher in vitro ligand binding and neutralization activity compared with the monovalent ectodomain (TßRII-ED), and a similar or slightly better potency than pan-TGF-ß-neutralizing antibody 1D11 or an Fc-fused receptor trap (TßRII-Fc). Despite its short in vivo half-life (<1 hour), which is primarily due to kidney clearance, daily injections of the (TßRII)2 trap reduced the growth of 4T1 tumors in BALB/c mice by 50%, an efficacy that is comparable with 1D11 (dosed thrice weekly). In addition, (TßRII)2 treatment of mice with established 4T1 tumors (100 mm(3)) significantly inhibited further tumor growth, whereas the 1D11 antibody did not. Overall, our results indicate that our rationally designed bivalent, single-chain traps have promising therapeutic potential.


Asunto(s)
Ingeniería de Proteínas , Receptores de Factores de Crecimiento Transformadores beta/química , Factor de Crecimiento Transformador beta/antagonistas & inhibidores , Animales , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Femenino , Orden Génico , Humanos , Terapia de Inmunosupresión , Ligandos , Masculino , Ratones , Ratones Endogámicos BALB C , Modelos Moleculares , Unión Proteica , Conformación Proteica , Estabilidad Proteica , Ratas , Ratas Sprague-Dawley , Receptores de Factores de Crecimiento Transformadores beta/genética , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/farmacología , Factor de Crecimiento Transformador beta/metabolismo
9.
J Neurosci ; 25(27): 6263-70, 2005 Jul 06.
Artículo en Inglés | MEDLINE | ID: mdl-16000615

RESUMEN

"Fierce" mice, homozygous for the deletion of nuclear receptor 2E1 (NR2E1), show abnormal brain-eye development and pathological aggression. To evaluate functional equivalency between mouse and human NR2E1, we generated mice transgenic for a genomic clone spanning the human NR2E1 locus and bred these animals to fierce mice deleted for the corresponding mouse gene. In fierce mutants carrying human NR2E1, structural brain defects were eliminated and eye abnormalities ameliorated. Excitingly, behavior in these "rescue" mice was indistinguishable from controls. Because no artificial promoter was used to drive transgene expression, promoter and regulatory elements within the human NR2E1 clone are functional in mouse. Normal behavior in rescue animals suggests that mechanisms underlying the behavioral abnormalities in fierce mice may also be conserved in humans. Our data support the hypothesis that variation at NR2E1 may contribute to human behavioral disorders. Use of this rescue paradigm with other genes will permit the direct evaluation of human genes hypothesized to play a causal role in psychiatric disease but for which evidence is lacking or equivocal.


Asunto(s)
Agresión/fisiología , Encéfalo/anomalías , Anomalías del Ojo/genética , Receptores Citoplasmáticos y Nucleares/deficiencia , Receptores Citoplasmáticos y Nucleares/fisiología , Conducta Agonística/fisiología , Animales , Encéfalo/embriología , Corteza Cerebral/anomalías , Anomalías Congénitas/embriología , Anomalías Congénitas/genética , Anomalías Congénitas/terapia , Cruzamientos Genéticos , Conducta Exploratoria/fisiología , Anomalías del Ojo/embriología , Anomalías del Ojo/terapia , Femenino , Genotipo , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Transgénicos , Bulbo Olfatorio/anomalías , Receptores Nucleares Huérfanos , Fenotipo , Regiones Promotoras Genéticas , Receptores Citoplasmáticos y Nucleares/química , Receptores Citoplasmáticos y Nucleares/genética , Secuencias Reguladoras de Ácidos Nucleicos , Retina/anomalías , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Especificidad de la Especie , Territorialidad
10.
J Neurosci ; 25(16): 4169-80, 2005 Apr 20.
Artículo en Inglés | MEDLINE | ID: mdl-15843620

RESUMEN

Huntington's disease (HD) is an adult-onset neurodegenerative disorder involving motor dysfunction, cognitive deficits, and psychiatric disturbances that result from underlying striatal and cortical dysfunction and neuropathology. The YAC128 mouse model of HD reproduces both the motor deficits and selective degeneration observed in the human disease. However, the presence of cognitive impairment in this model has not been determined. Here, we report mild cognitive deficits in YAC128 mice that precede motor onset and progressively worsen with age. Rotarod testing revealed a motor learning deficit at 2 months of age that progresses such that by 12 months of age, untrained YAC128 mice are unable to learn the rotarod task. Additional support for cognitive dysfunction is evident in a simple swimming test in which YAC128 mice take longer to find the platform than wild-type (WT) controls beginning at 8 months of age. YAC128 mice also have deficits in open-field habituation and in a swimming T-maze test at this age. Strikingly, in the reversal phase of the swimming T-maze test, YAC128 mice take twice as long as WT mice to locate the platform, indicating a difficulty in changing strategy. At 12 months of age, YAC128 mice show decreased prepulse inhibition and habituation to acoustic startle. The clear pattern of cognitive dysfunction in YAC128 mice is similar to the symptoms and progression of cognitive deficits in human HD and provides both the opportunity to examine the relationship between cognitive dysfunction, motor impairment, and neuropathology in HD and to assess whether potential therapies for HD can restore cognitive function.


Asunto(s)
Trastornos del Conocimiento/etiología , Enfermedad de Huntington/patología , Enfermedad de Huntington/fisiopatología , Trastornos del Movimiento/etiología , Estimulación Acústica/efectos adversos , Factores de Edad , Análisis de Varianza , Animales , Conducta Animal , Modelos Animales de Enfermedad , Relación Dosis-Respuesta en la Radiación , Conducta Exploratoria/fisiología , Habituación Psicofisiológica , Enfermedad de Huntington/genética , Inhibición Psicológica , Aprendizaje por Laberinto/fisiología , Memoria/fisiología , Ratones , Actividad Motora/genética , Actividad Motora/fisiología , Desempeño Psicomotor/fisiología , Reflejo Acústico/fisiología , Prueba de Desempeño de Rotación con Aceleración Constante/métodos , Natación/fisiología , Factores de Tiempo
11.
Hum Mol Genet ; 12(13): 1555-67, 2003 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-12812983

RESUMEN

An expanded CAG repeat is the underlying genetic defect in Huntington disease, a disorder characterized by motor, psychiatric and cognitive deficits and striatal atrophy associated with neuronal loss. An accurate animal model of this disease is crucial for elucidation of the underlying natural history of the illness and also for testing experimental therapeutics. We established a new yeast artificial chromosome (YAC) mouse model of HD with the entire human HD gene containing 128 CAG repeats (YAC128) which develops motor abnormalities and age-dependent brain atrophy including cortical and striatal atrophy associated with striatal neuronal loss. YAC128 mice exhibit initial hyperactivity, followed by the onset of a motor deficit and finally hypokinesis. The motor deficit in the YAC128 mice is highly correlated with striatal neuronal loss, providing a structural correlate for the behavioral changes. The natural history of HD-related changes in the YAC128 mice has been defined, demonstrating the presence of huntingtin inclusions after the onset of behavior and neuropathological changes. The HD-related phenotypes of the YAC128 mice show phenotypic uniformity with low inter-animal variability present, which together with the age-dependent striatal neurodegeneration make it an ideal mouse model for the assessment of neuroprotective and other therapeutic interventions.


Asunto(s)
Enfermedad de Huntington/metabolismo , Enfermedad de Huntington/patología , Proteínas del Tejido Nervioso/genética , Neuronas/metabolismo , Proteínas Nucleares/genética , Factores de Edad , Animales , Southern Blotting , Encéfalo/patología , Encéfalo/ultraestructura , Cromosomas Artificiales de Levadura , Modelos Animales de Enfermedad , Humanos , Proteína Huntingtina , Enfermedad de Huntington/genética , Ratones , Microscopía Electrónica , Mutagénesis , Neuronas/patología , Fenotipo , ARN/metabolismo , Factores de Tiempo , Repeticiones de Trinucleótidos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...